Molecular mechanisms underlying corticosteroid unresponsiveness in the treatment of systemic lupus erythematosus
- Author:
- No author available
- Journal Title:
- INTERNATIONAL JOURNAL OF DERMATOLOGY AND VENEREOLOGY
- Issue:
- 3
- DOI:
- 10.3760/cma.j.issn.1673-4173.2009.03.008
- Key Word:
- 红斑狼疮,系统性;糖皮质激素类;糖蛋白类;治疗失败;Lupus erythematosus,systemic;Glucocorticoid;Glycoproteins;Treatment failure
Abstract： It is an awkward issue to treat systemic lupus erythematosus(SLE)in patients with corticosteroid unresponsiveness.Recently,P-glycoprotein(P-gP)and macrophage migration inhibition factor (MIF)have been clearly linked to the modulation of corticosteroid sensitivity.The following two mechanisms seem to be involved in corticosteroid unresponsiveness.First,over-expression of P-gp on activated peripheral lymphocytes can cause the exclusion of intercellular corticosteroid from lymphocytes.Second,the expression Of MIF.which exerts a potent antagonistic effect on corticosteroid suppression of immune-mediated inflammation.is increased in patients with SLE.It may restore the sensitivity to corticosteroid to down-regulate or suppress the expression of P-gp and MIF in patients with SLE.
- [1]陈伟英,李广然,方芳,等.外周血单个核细胞巨噬细胞移动抑制因子表达及其与狼疮活动[J].2004,(8).
- [2]Hughes GR,D'Cruz DP,Khamashta MA.Systemic lupus erythematosus.[J].2007,369(9561).
- [3]Chies JA,Silveira IG,Bauer ME,etc.Is steroid resistance related to multidrug resistance-I (MDR-I) in rheumatoid arthritis?[J].2007,7(6).
- [4]Kelleher D,Farrell RJ.Glucocorticoid resistance in inflammatory bowel disease.[J].2003,178(3).
- [5]Lori B, Tucker.Controversies and advances in the management of systemic lupus erythematosus in children and adolescents.[J].2002,16(3).
- [6]Ignacio Rodriguez,Darrell R. Abernethy,Raymond L. Woosley.P-Glycoprotein in Clinical Cardiology[J].1999,99(4).
- [7]Aeberli D,Morand EF,Leech M.Macrophage migration inhibitory factor and glucocorticoid sensitivity.[J].2006,45(8).
- [8]King JK,Hahn BH.Systemic lupus erythematosus: modern strategies for management - a moving target.[J].2007,21(6).
- [9]Flaster H,Bernhagen J,Calandra T,etc.The macrophage migration inhibitory factor-glucocorticoid dyad: Regulation of inflammation and immunity[J].2007,21(6).
- [10]Tanaka Y,Nawata M,Nakayamada S,etc.Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis.[J].2008,67(3).
- [11]Foote A,Briganti EM,Kipen Y,etc.Macrophage migration inhibitory factor in systemic lupus erythematosus.[J].2004,31(2).
- [12]Tanaka Y,Tsujimura S,Nakayamada S,etc.Relevance of multidrug resistance 1 and P-glycoprotein to drug resistance in patients with systemic lupus erythematosus.[J].2007,22(4).
- [13]Richaud-Patin, Y.,Soto-Vega, E.,Jakez-Ocampo, J.,etc.P-glycoprotein in autoimmune diseases[J].2004,3(3).
- [14]Landini I,Nobili S,Mini E,etc.Pharmacological strategies for overcoming multidrug resistance.[J].2006,7(7).
- [15]Zoch-Zwierz W,Pietruczuk M,Wasilewska A.Expression of multidrug resistance P-glycoprotein on lymphocytes from nephrotic children treated with cyclosporine A and ACE-inhibitor.[J].2007,166(5).
- [16]Mikiko Tokunaga,Kazuyoshi Saito,Kazuhisa Nakano,etc.Overcoming treatment unresponsiveness mediated by P-glycoprotein overexpression on lymphocytes in refractory active systemic lupus erythematosus[J].2005,15(1).
- [17]Kayo Henmi,Masaharu Yoshida.P-Glycoprotein Functions in Peripheral-Blood CD4<sup>+</sup> Cells of Patients with Systemic Lupus Erythematosus[J].2008,31(5).